BACKGROUND: Endothelial activation has emerged as an early event in the pathogenesis of cardiovascular disease. Angiopoietin-2 (Ang-2) has been identified as a nonredundant endothelial-specific facilitator of vascular responsiveness to inflammatory stimuli. We have earlier shown that angiotensin II receptor blocker (ARB) reduces mediators of vascular inflammation in hypertension and cardiovascular disease. We aimed at studying the effect of ARB and/or 3-hydroxy-3-methyl-glutaryl-CoA blockade on Ang-2 and the association between vascular inflammation markers and Ang-2 levels in hypertensive patients. METHODS: We assessed a panel of vascular inflammation markers and Ang-2 during 12 weeks of therapy with the ARB olmesartan (n = 94) or placebo (n = 96) in a prospective, double-blind, multicenter study in patients with essential hypertension (re-evaluation of the European Trial onOlmesartan and Pravastatinin Inflammation blood samples). Pravastatin was added to the double-blind therapy at week 6 in both arms. The association of demographic variables and inflammation markers with Ang-2 has been investigated. RESULTS:Initial Ang-2 concentrations in the study population were elevated compared with healthy controls (4.23 +/- 3.1 versus 0.88 +/- 0.43 ng/ml; P < 0.0001). Ang-2 was higher in the elderly (P = 0.01), women (P < 0.001), and in the presence of atherosclerosis (P = 0.02). Ang-2 correlated significantly with soluble TEK tyrosine kinase-2, interleukin-6, vascular cell adhesionmolecule-1, and inter-cellular adhesion molecule-1. Surprisingly, neither monotherapy with olmesartan or pravastatin nor the combination therapy affected Ang-2 concentrations. CONCLUSION: Ang-2 concentrations are elevated in hypertensive patients, particularly those with atherosclerosis, possibly reflecting pronounced endothelial activation. ARBs effectively decreased several inflammatory mediators, but did not affect vascular responsiveness in an Ang-2-dependent manner. Elevated Ang-2 levels in hypertensive patients correlate with adhesion molecules.
RCT Entities:
BACKGROUND: Endothelial activation has emerged as an early event in the pathogenesis of cardiovascular disease. Angiopoietin-2 (Ang-2) has been identified as a nonredundant endothelial-specific facilitator of vascular responsiveness to inflammatory stimuli. We have earlier shown that angiotensin II receptor blocker (ARB) reduces mediators of vascular inflammation in hypertension and cardiovascular disease. We aimed at studying the effect of ARB and/or 3-hydroxy-3-methyl-glutaryl-CoA blockade on Ang-2 and the association between vascular inflammation markers and Ang-2 levels in hypertensivepatients. METHODS: We assessed a panel of vascular inflammation markers and Ang-2 during 12 weeks of therapy with the ARB olmesartan (n = 94) or placebo (n = 96) in a prospective, double-blind, multicenter study in patients with essential hypertension (re-evaluation of the European Trial on Olmesartan and Pravastatin in Inflammation blood samples). Pravastatin was added to the double-blind therapy at week 6 in both arms. The association of demographic variables and inflammation markers with Ang-2 has been investigated. RESULTS: Initial Ang-2 concentrations in the study population were elevated compared with healthy controls (4.23 +/- 3.1 versus 0.88 +/- 0.43 ng/ml; P < 0.0001). Ang-2 was higher in the elderly (P = 0.01), women (P < 0.001), and in the presence of atherosclerosis (P = 0.02). Ang-2 correlated significantly with soluble TEK tyrosine kinase-2, interleukin-6, vascular cell adhesion molecule-1, and inter-cellular adhesion molecule-1. Surprisingly, neither monotherapy with olmesartan or pravastatin nor the combination therapy affected Ang-2 concentrations. CONCLUSION:Ang-2 concentrations are elevated in hypertensivepatients, particularly those with atherosclerosis, possibly reflecting pronounced endothelial activation. ARBs effectively decreased several inflammatory mediators, but did not affect vascular responsiveness in an Ang-2-dependent manner. Elevated Ang-2 levels in hypertensivepatients correlate with adhesion molecules.
Authors: Soundarya N Selvam; Lara J Casey; Mackenzie L Bowman; Lindsey G Hawke; Avery J Longmore; Jeffrey Mewburn; Mark L Ormiston; Stephen L Archer; Donald H Maurice; Paula James Journal: Blood Coagul Fibrinolysis Date: 2017-10 Impact factor: 1.276
Authors: Julia C F Quintanilha; Yingmiao Liu; Amy S Etheridge; Akram Yazdani; Hedy L Kindler; William Kevin Kelly; Andrew B Nixon; Federico Innocenti Journal: Angiogenesis Date: 2021-05-24 Impact factor: 9.596
Authors: Philipp Kümpers; Matijs van Meurs; Sascha David; Grietje Molema; Johan Bijzet; Alexander Lukasz; Frank Biertz; Hermann Haller; Jan G Zijlstra Journal: Crit Care Date: 2009-05-05 Impact factor: 9.097